1356565-46-2

Basic information

• Product Name: N-DESMETHYL IMATINIB
• Synonyms: N-DESMETHYL GLEEVEC;N-DESMETHYL IMATINIB;Imatinib desmethyl (as formate)
• CAS NO: 1356565-46-2
• Molecular Formula: C28H29N7O
• Molecular Weight: 479.58
• Mol File: 1356565-46-2.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.248±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 13.20±0.70(Predicted)
• CAS DataBase Reference: N-DESMETHYL IMATINIB(CAS DataBase Reference)
• NIST Chemistry Reference: N-DESMETHYL IMATINIB(1356565-46-2)
• EPA Substance Registry System: N-DESMETHYL IMATINIB(1356565-46-2)

Safety Data

• Hazardous Substances Data: 1356565-46-2(Hazardous Substances Data)

Usage

Description

N-DESMETHYL IMATINIB, also known as Imatinib EP Impurity C, is a metabolite of Gleevec (G407000), a tyrosine kinase inhibitor that is highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). It has been identified as a COVID-19-related research product, indicating its potential role in the study and treatment of the virus.

Uses

Used in Pharmaceutical Industry:
N-DESMETHYL IMATINIB is used as an active pharmaceutical ingredient (API) for the treatment of chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). It targets the BCR-ABL enzyme, which is a key factor in the development of these blood cancers.
Used in COVID-19 Research:
N-DESMETHYL IMATINIB is used as a research compound for COVID-19-related studies. Its role in this context is to explore its potential as a therapeutic agent against the virus, possibly through its effects on specific cellular pathways or interactions with other molecules involved in the disease process.
Used in Drug Metabolism Studies:
As a metabolite of Gleevec, N-DESMETHYL IMATINIB is used in drug metabolism research to understand the biotransformation processes of the parent drug, Gleevec, in the body. This knowledge can help optimize drug dosages, predict potential drug-drug interactions, and improve the overall safety and efficacy of the treatment.